Showing results (491-500 of 831) with videos related to

Sort By:
Pageof 84
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 2, 2025
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemiaRachel J Bailen, Monica I Aasum, Linda M Tamminga, et al.
Blood|September 30, 2006
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E Kay, Susan M Geyer, Timothy G Call, et al.
British Journal of Haematology|April 16, 2003
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemiaGordon W Dewald, Stephanie R Brockman, Sarah F Paternoster, et al.
Blood|June 26, 2008
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaLaura Z Rassenti, Sonia Jain, Michael J Keating, et al.
Blood|April 2, 2009
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cellsAsish K Ghosh, Tait D Shanafelt, Amelia Cimmino, et al.
Blood|December 2, 2004
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, et al.
Blood|December 9, 2008
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapyElias Jabbour, Hagop M Kantarjian, Dan Jones, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
The Lancet. Haematology|December 22, 2015
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsKoji Sasaki, Sara S Strom, Susan O'Brien, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Pageof 84